celastrol has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, X; Guo, H; Hu, R; Huang, S; Li, Z; Liang, L; Liu, Z; Qiu, X; Tan, Q; Wang, Y; Wu, D; Zhou, B | 1 |
1 other study(ies) available for celastrol and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.
Topics: Animals; DNA; Humans; Ligases; Male; Mice; Pentacyclic Triterpenes; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Receptors, Glucocorticoid; Ubiquitin-Protein Ligases; Ubiquitins | 2022 |